Change to Novonesis’ Board of Directors
17 déc. 2024 04h00 HE
|
Novonesis (Novozymes A/S)
Sharon James will not be seeking re-election to the Board of Directors of Novonesis at the upcoming annual general meeting in 2025 and will step down effectively on December 31, 2024. This decision...
Major shareholder announcement
29 nov. 2024 09h22 HE
|
Novonesis (Novozymes A/S)
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
Major shareholder announcement
27 nov. 2024 05h09 HE
|
Novonesis (Novozymes A/S)
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
Major shareholder announcement
25 nov. 2024 07h43 HE
|
Novonesis (Novozymes A/S)
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
Trading by management and close relations of management
20 nov. 2024 09h44 HE
|
Novonesis (Novozymes A/S)
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016,...
Novonesis will host an educational conference call on Energy on December 18
18 nov. 2024 07h54 HE
|
Novonesis (Novozymes A/S)
Novonesis will host a spotlight educational session on our Energy activities which is part of Planetary Health Biosolutions. We will share insights about the industry, its development, and Novonesis’...
Major shareholder announcement
13 nov. 2024 06h57 HE
|
Novonesis (Novozymes A/S)
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital...
Q3 update: Novonesis delivers strong Q3 results and now expects full-year organic sales growth at the upper end of 7-8%
07 nov. 2024 02h02 HE
|
Novonesis (Novozymes A/S)
Following increasing demand in the first nine months of the 2024 financial year, Novonesis delivers 9% organic sales growth with a strong 11% organic sales growth in the third quarter. The strong...
Trading statement 9M 2024
07 nov. 2024 01h59 HE
|
Novonesis (Novozymes A/S)
Organic pro forma sales growth of 9%, including 11% in the third quarter. Full-year organic sales growth outlook now expected at the upper end of the 7-8% range and the adjusted EBITDA margin...
Trading by management and close relations of management
04 nov. 2024 07h21 HE
|
Novonesis (Novozymes A/S)
Announcement released on November 4, 2024 at 10:07:51 CET did not include PDF file. Please see the full announcement in the attached PDF file.
Attachment
...